Business Wire

NORTHERN-DATA-AG

21.7.2020 07:34:11 CEST | Business Wire | Press release

Share
Northern Data AG: Successful Development Partnership With Gigabyte Technology

Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87 ), one of the world's largest providers of high-performance-computing (HPC) solutions, has developed proprietary HPC services in cooperation with the leading Taiwanese computer hardware manufacturer Gigabyte Technology (Taiwan Stock Exchange: 2376, ISIN: TW0002376001 ).

Northern Data's partnership with Gigabyte covers the production, supply and combination of components, where Northern Data tests specific processors (GPUs, CPUs, etc.) and selects them for the respective applications and Gigabyte combines these processors with its specialised server architecture. In doing so, Gigabyte adjusts the GPU clusters developed by Northern Data to meet all of Northern Data's technical requirements. A GPU cluster is a computer network in which each node (processing unit) is equipped with several Graphic Processing Units (GPU). The high-density GPU clusters used in these processes are specially designed for high-performance-computing (HPC) applications.

The server architecture created on this basis is the foundation for so-called distributed computing. Distributed computing involves running software across multiple computer systems working in parallel, in order to increase their efficiency, reliability and performance. With these new, tailor-made high-density GPU clusters, Northern Data can meet the highly specific requirements of their customers, providing them with the required computing power for their respective HPC applications as easily and efficiently as possible. This service will then be used in Northern Data's data centers for individually developed customer solutions.

GPU-based, parallel processing of data enables highly complex, computationally intensive HPC applications to be executed efficiently, reliably and quickly, particularly in the domains of artificial intelligence and rendering.

This combination of Gigabyte's expertise in manufacturing HPC hardware and Northern Data's experience in managing and orchestrating large-scale facilities (with proprietary AI software and its own thermal management system) opens up new opportunities for Northern Data customers to scale their operations even further than before. Northern Data distinguishes itself from other providers by the composition and combination of hardware and software, the way it is made available and, above all, by the favourable pricing for customers.

"The demand for HPC is booming; the rendering and AI sectors are enormous growth markets. We are pleased to have Gigabyte Technologies, one of the leading suppliers in the young HPC sector, on board as our development partner, and we are now excited to announce this business partnership," explains Aroosh Thillainathan, CEO of Northern Data AG, and continues: "We have already worked together on various GPU-based HPC projects, as we believe that Gigabyte's servers are among the best hardware for HPC in the world. Hence, we are very pleased to deepen our partnership with a manufacturer with this level of expertise and to have them accompany our R&D process. Gigabyte is the right strategic partner to help us make the concept of distributed computing a reality for many HPC applications".

Northern Data CFO Mathis Schultz adds: "So far, our customers are predominantly in the bitcoin mining sector, which was the first mass-scale HPC application. But the demand from other sectors is growing rapidly, accelerated in part by the Covid-19 crisis. The partnership with Gigabyte Technologies allows us to build out our market-leading position with bitcoin mining clients, into new sectors."

And Thomas Yen, European head of Gigabyte Technologies explains: "We are pleased to now officially announce our partnership with Northern Data. We see great potential in our jointly-designed GPU clusters. We are excited to work closely with Northern Data as a strategic partner and high-potential customer in the field of HPC."

About Northern Data:

Northern Data AG builds and offers global infrastructure solutions in the field of high-performance computing (HPC), offering solutions in the fields of machine learning and artificial intelligence, big data analytics, blockchain applications, game streaming and more. Operating internationally the company evolved from the merger of German Northern Bitcoin AG and American Whinstone US, Inc. and is now a recognized leader in the provision of HPC solutions worldwide. The company offers HPC solutions, both stationary in large state-of-the-art data centers as well as in high-tech mobile data centers, which can be deployed in any location worldwide. In doing so, it combines self-developed software and hardware with novel concepts to ensure a sustainable and reliable energy supply. In Texas, Northern Data is running the USA's largest HPC data center and, at the same time, the world's largest dedicated HPC facility. Further information can be found at www.northerndata.de .

About Gigabyte Technology Co., Ltd.

Gigabyte Technology Co., Ltd. is a Taiwan-based company principally engaged in the production, processing and sales of information technology (IT) products. The company provides computer motherboards, three dimensional (3D) display graphic cards, laptops, tablets, personal computers (PCs), servers, smart phones, broadband network devices and wireless communication products, computer peripherals and network storage products. It distributes its products mainly within Taiwan, as well as to the rest of Asia, Europe and the Americas.

Disclaimer:

This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice.

Language: English
Company: Northern Data AG
Thurn-und-Taxis-Platz 6
60313 Frankfurt/Main
Germany
Phone: +49 69 34 87 52 25
E-mail: info@northerndata.de
Internet: www.northerndata.de
ISIN: DE000A0SMU87
WKN: A0SMU8
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange
EQS News ID:

1097883

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye